ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships
Western and China companies are leveraging the significant funding and support available in China to develop their assets more cost effectively and efficiently. 2016 set another record in VC funds raised (USD 15 billion) and invested (USD 5.8 billion) in life science in China. And partnering activity has continued to be strong, with over USD 8 billion in deal value created in 2015 and 2016. Highly active VCs, CROs and Western and China pharma companies discuss how they can serve as financial and strategic partners.